Cargando…
A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale
AIM: Attenuated psychosis syndrome (APS), a condition for further study in the Diagnostic and Statistical Manual of Mental Disorders‐5, comprises psychotic symptoms that are qualitatively similar to those observed in schizophrenia but are less severe. Patients with APS are at high risk of converting...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451588/ https://www.ncbi.nlm.nih.gov/pubmed/33354862 http://dx.doi.org/10.1111/eip.13083 |
_version_ | 1784569878629318656 |
---|---|
author | Keefe, Richard S. E. Woods, Scott W. Cannon, Tyrone D. Ruhrmann, Stephan Mathalon, Daniel H. McGuire, Philip Rosenbrock, Holger Daniels, Kristen Cotton, Daniel Roy, Dooti Pollentier, Stephane Sand, Michael |
author_facet | Keefe, Richard S. E. Woods, Scott W. Cannon, Tyrone D. Ruhrmann, Stephan Mathalon, Daniel H. McGuire, Philip Rosenbrock, Holger Daniels, Kristen Cotton, Daniel Roy, Dooti Pollentier, Stephane Sand, Michael |
author_sort | Keefe, Richard S. E. |
collection | PubMed |
description | AIM: Attenuated psychosis syndrome (APS), a condition for further study in the Diagnostic and Statistical Manual of Mental Disorders‐5, comprises psychotic symptoms that are qualitatively similar to those observed in schizophrenia but are less severe. Patients with APS are at high risk of converting to first‐episode psychosis (FEP). As evidence for effective pharmacological interventions in APS is limited, novel treatments may provide symptomatic relief and delay/prevent psychotic conversion. This trial aims to investigate the efficacy, safety, and tolerability of BI 409306, a potent and selective phosphodiesterase‐9 inhibitor, versus placebo in APS. Novel biomarkers of psychosis are being investigated. METHODS: In this Phase II, multinational, double‐blind, parallel‐group trial, randomized (1:1) patients will receive BI 409306 50 mg or placebo twice daily for 52 weeks. Patients (n = 300) will be enrolled to determine time to remission of APS, time to FEP, change in everyday functional capacity (Schizophrenia Cognition Rating Scale), and change from baseline in Brief Assessment of Cognition composite score and Positive and Negative Syndrome Scale scores. Potential biomarkers of psychosis under investigation include functional measures of brain activity and automated speech analyses. Safety is being assessed throughout. CONCLUSIONS: This trial will determine whether BI 409306 is superior to placebo in achieving sustainable remission of APS and improvements in cognition and functional capacity. These advances may provide evidence‐based treatment options for symptomatic relief in APS. Furthermore, the study will assess the effect of BI 409306 on psychotic conversion and explore the identification of patients at risk for conversion using novel biomarkers. |
format | Online Article Text |
id | pubmed-8451588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wiley Publishing Asia Pty Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84515882021-09-27 A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale Keefe, Richard S. E. Woods, Scott W. Cannon, Tyrone D. Ruhrmann, Stephan Mathalon, Daniel H. McGuire, Philip Rosenbrock, Holger Daniels, Kristen Cotton, Daniel Roy, Dooti Pollentier, Stephane Sand, Michael Early Interv Psychiatry Original Articles AIM: Attenuated psychosis syndrome (APS), a condition for further study in the Diagnostic and Statistical Manual of Mental Disorders‐5, comprises psychotic symptoms that are qualitatively similar to those observed in schizophrenia but are less severe. Patients with APS are at high risk of converting to first‐episode psychosis (FEP). As evidence for effective pharmacological interventions in APS is limited, novel treatments may provide symptomatic relief and delay/prevent psychotic conversion. This trial aims to investigate the efficacy, safety, and tolerability of BI 409306, a potent and selective phosphodiesterase‐9 inhibitor, versus placebo in APS. Novel biomarkers of psychosis are being investigated. METHODS: In this Phase II, multinational, double‐blind, parallel‐group trial, randomized (1:1) patients will receive BI 409306 50 mg or placebo twice daily for 52 weeks. Patients (n = 300) will be enrolled to determine time to remission of APS, time to FEP, change in everyday functional capacity (Schizophrenia Cognition Rating Scale), and change from baseline in Brief Assessment of Cognition composite score and Positive and Negative Syndrome Scale scores. Potential biomarkers of psychosis under investigation include functional measures of brain activity and automated speech analyses. Safety is being assessed throughout. CONCLUSIONS: This trial will determine whether BI 409306 is superior to placebo in achieving sustainable remission of APS and improvements in cognition and functional capacity. These advances may provide evidence‐based treatment options for symptomatic relief in APS. Furthermore, the study will assess the effect of BI 409306 on psychotic conversion and explore the identification of patients at risk for conversion using novel biomarkers. Wiley Publishing Asia Pty Ltd 2020-12-22 2021-10 /pmc/articles/PMC8451588/ /pubmed/33354862 http://dx.doi.org/10.1111/eip.13083 Text en © 2020 The Authors. Early Intervention in Psychiatry published by John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Keefe, Richard S. E. Woods, Scott W. Cannon, Tyrone D. Ruhrmann, Stephan Mathalon, Daniel H. McGuire, Philip Rosenbrock, Holger Daniels, Kristen Cotton, Daniel Roy, Dooti Pollentier, Stephane Sand, Michael A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale |
title | A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale |
title_full | A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale |
title_fullStr | A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale |
title_full_unstemmed | A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale |
title_short | A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale |
title_sort | randomized phase ii trial evaluating efficacy, safety, and tolerability of oral bi 409306 in attenuated psychosis syndrome: design and rationale |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451588/ https://www.ncbi.nlm.nih.gov/pubmed/33354862 http://dx.doi.org/10.1111/eip.13083 |
work_keys_str_mv | AT keeferichardse arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT woodsscottw arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT cannontyroned arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT ruhrmannstephan arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT mathalondanielh arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT mcguirephilip arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT rosenbrockholger arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT danielskristen arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT cottondaniel arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT roydooti arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT pollentierstephane arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT sandmichael arandomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT keeferichardse randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT woodsscottw randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT cannontyroned randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT ruhrmannstephan randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT mathalondanielh randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT mcguirephilip randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT rosenbrockholger randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT danielskristen randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT cottondaniel randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT roydooti randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT pollentierstephane randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale AT sandmichael randomizedphaseiitrialevaluatingefficacysafetyandtolerabilityoforalbi409306inattenuatedpsychosissyndromedesignandrationale |